Drugs in Pipeline
11
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Mar 15, 2026
| Drug Name | Phase |
|---|---|
Elebsiran | Phase 3 |
VIR-7831 (sotrovimab) | Phase 3 |
Tobevibart | Phase 3 |
VIR-2218 | Phase 2 |
pegylated interferon-alfa 2a | Phase 2 |
Placebo | Phase 2 |
VIR-5818 | Phase 2 |
VIR-3434 | Phase 2 |
Bulevirtide | Phase 2 |
Sotrovimab (Gen1) | Phase 2 |
NRTI | Phase 2 |
4 upcoming, 0 past
Primary completion for VIR-2218 trial (NCT04856085) in Hepatitis B, Chronic
SourcePrimary completion for Bulevirtide trial (NCT07142811) in Viral Hepatitis
SourcePrimary completion for Elebsiran trial (NCT07142811) in Viral Hepatitis
SourcePrimary completion for Tobevibart trial (NCT07142811) in Viral Hepatitis
Source